Nasir Khan，兽医学博士、博士：临床前开发高级副总裁Gary Ingenito，医学博士、博士：临床开发高级副总裁 沃尔瑟姆，马萨诸塞州, Oct. 22, 2025 (GLOBE NEWSWIRE) -- 维泰瑞隆是一家处于临床阶段的全球化生物科技公司，致力于探索和开发用于治疗衰老相关疾病的变革性疗法。公司今日宣布任命Nasir Khan，兽医学博士、博士，为临床前开发高级副总裁，任命自2025年10月20日起生效；任命Gary Ingenito，医学博士、博士，为临床开发高级副总裁，任命自2025年11月1日起生效。两位将在公司位于马萨诸塞州沃尔瑟姆的行政总部工作，向维泰瑞隆总裁兼首席执行官Dr. Shefali Agarwal汇报。 Dr. Agarwal表示：“我们很高兴并欢迎两位杰出领导者的加入，这将帮助公司进一步壮大和推进我们的研发管线，其中包括三个临床阶段项目、四个有望成为同类首创或同类最佳的分子，以及若干早期临床前项目。Nasir Khan博士和Gary Ingenito博士在全球药物发现和开发领域拥有深厚的专业积累，并且推动了多个对患者具有重大意义的创新疗法的诞生。我们期待两位领导者 ...

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has announced a delay in the completion of certain fundraising investment projects, specifically extending the expected operational date for the raw material drug phase II project to July 2026, due to ongoing technical improvements and to ensure project quality [1][4][5]. Fundraising Overview - The company was approved to issue up to 45.38 million shares, with an actual issuance of 41,046,070 shares at a price of 12.52 yuan per share, raising a total of approximately 513.90 million yuan, netting about 502.38 million yuan after deducting issuance costs [1][2]. - As of June 30, 2025, the actual amount used for fundraising projects was approximately 496.15 million yuan, leaving a remaining balance of about 26.41 million yuan [2][3]. Investment Project Details - The company has made adjustments to several fundraising projects, including the cancellation of some projects and the reallocation of funds to others, such as the raw material drug phase II project and the development of anti-tumor drugs [2][3]. - The company has also permanently supplemented working capital with surplus funds from completed projects, ensuring ongoing operational support [3][4]. Delay Reasons and Measures - The delay in the raw material drug phase II project is attributed to the need for further technical improvements, with the first phase of construction completed and the second phase still in progress [4]. - The company plans to adhere to regulatory requirements and optimize resource allocation to ensure timely completion of the projects despite the delays [4][5]. Approval Process - The board of directors and the supervisory board of the company approved the delay in the project timeline on August 28, 2025, without requiring shareholder approval [5][6]. - The sponsor institution has confirmed that the decision complies with relevant regulations and does not alter the intended use of the raised funds or harm shareholder interests [5][6].

Core Points - The company plans to use part of its idle raised funds to temporarily supplement working capital, with an amount not exceeding 12 million RMB and a duration of no more than 12 months from the board's approval date [1][4]. Summary of Fundraising Situation - The company was approved to issue up to 45.38 million new shares, with an actual issuance of 41,046,070 shares at a price of 12.52 RMB per share, raising a total of approximately 513.90 million RMB, netting about 502.38 million RMB after deducting issuance costs [1][2]. - As of June 16, 2025, the actual amount used for fundraising projects was approximately 496.14 million RMB, leaving a remaining amount of approximately 26.41 million RMB [2]. Summary of Fundraising Investment Projects - The company has several projects with varying levels of investment and usage, including: - National Class I anti-cancer drug project with a committed investment of 156.10 million RMB, with 34.94 million RMB used [2]. - Raw material drug project with a committed investment of 46 million RMB, fully utilized [2]. - Automation warehouse project with a committed investment of 36.80 million RMB, with 8.12 million RMB used [2]. - The total amount for temporary working capital supplementation is set at 12 million RMB [3][4]. Approval Process for Fund Usage - The board and supervisory committee approved the plan to use idle funds on June 25, 2025, ensuring compliance with relevant regulations and that it would not affect the normal progress of fundraising investment projects [4][5]. - The supervisory committee and the sponsor institution both expressed support for the plan, confirming it aligns with regulatory requirements and does not harm shareholder interests [5].